The cardiovascular system medicine sales in Belgium experienced a notable declining trend from 2013 to 2023. Starting at $1.04 billion in 2013, sales dropped significantly by 2023 to $0.6043 billion. Year-on-year variations indicate a general decline, with notable annual decreases such as -19.08% in 2015 and -6.99% in 2022. The period witnessed slight positive growth only in 2021 at 1.51%. The compound annual growth rate (CAGR) over the last five years leading up to 2023 was -2.7%.
Forecasts indicate a continued decline, with a projected drop to $0.4845 billion by 2028. Future trends to watch for include:
- Advancements in cardiovascular treatments and their impact on sales.
- Policy changes in the healthcare sector influencing medication pricing.
- The adoption rate of alternative therapies and preventive measures.
